ImageneBio reports Q3 EPS ($2.91) vs. ($2.58) last year

Reports Q3 revenue $0 vs. $3.5M last year. “We are in a wonderful position as we complete our first quarter as a public company. Atopic dermatitis is a chronic, serious and highly prevalent inflammatory disease where new treatments are much needed. Despite the impressive multibillion dollar market size, today only around 15% of eligible patients receive advanced therapy including biologics, and more than a third of those patients do not receive sufficient relief from that treatment. We have spent our first few months as a new team engaging with our networks of top key opinion leaders, treating physicians, and other experts in atopic dermatitis, as well as gaining valuable insights from the recent, extensive OX40-targeting data shared by our peers,” commented Kristin Yarema, CEO. “Our recent learnings reinforce our belief that the anti-OX40/OX40L class, with its unique mechanism, is on a promising path towards adoption in atopic dermatitis and other inflammatory and autoimmune indications. However, the peer data to date also highlight the need for a differentiated anti-OX40 treatment that is safe and can be administered at optimal doses for maximum efficacy. Both thoughtful study design and high-quality execution are essential to achieve success-we must ‘sweat the small stuff.’ We believe IMG-007 is the only anti-OX40 in mid- to late-stage clinical development that is non-T cell depleting and receptor-targeting, with a roughly 5-week half-life. This combination of mechanistic and pharmacologic properties has the potential to offer a best-in-class profile for patients. As we continue to advance our ongoing Phase 2b trial, we intend to use our learnings to amend the study in ways that we believe will help us best demonstrate the differentiated potential of IMG-007.”